245 related articles for article (PubMed ID: 16211287)
21. FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre.
Bjurberg M; Gustavsson A; Ohlsson T; Brun E
Acta Oncol; 2006; 45(6):743-9. PubMed ID: 16938818
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long term follow-up results.
Molnar Z; Simon Z; Borbenyi Z; Deak B; Galuska L; Keresztes K; Miltenyi Z; Marton I; Rosta A; Schneider T; Tron L; Varady E; Illes A
Neoplasma; 2010; 57(4):349-54. PubMed ID: 20429626
[TBL] [Abstract][Full Text] [Related]
23. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S
Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053
[TBL] [Abstract][Full Text] [Related]
24. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures.
Picardi M; Pugliese N; Cirillo M; Zeppa P; Cozzolino I; Ciancia G; Pettinato G; Salvatore C; Quintarelli C; Pane F
Radiology; 2014 Jul; 272(1):262-74. PubMed ID: 24708193
[TBL] [Abstract][Full Text] [Related]
25. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma.
Bhojwani D; McCarville MB; Choi JK; Sawyer J; Metzger ML; Inaba H; Davidoff AM; Gold R; Shulkin BL; Sandlund JT
Br J Haematol; 2015 Mar; 168(6):845-53. PubMed ID: 25382494
[TBL] [Abstract][Full Text] [Related]
26. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
27. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas.
Mikhaeel NG; Timothy AR; Hain SF; O'Doherty MJ
Ann Oncol; 2000; 11 Suppl 1():147-50. PubMed ID: 10707798
[TBL] [Abstract][Full Text] [Related]
28. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
29. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Belhocine T; Hustinx R; Rigo P; Fillet G
Ann Oncol; 2003 Jan; 14(1):123-30. PubMed ID: 12488304
[TBL] [Abstract][Full Text] [Related]
30. Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial.
Furth C; Steffen IG; Amthauer H; Ruf J; Misch D; Schönberger S; Kobe C; Denecke T; Stöver B; Hautzel H; Henze G; Hundsdoerfer P
J Clin Oncol; 2009 Sep; 27(26):4385-91. PubMed ID: 19667276
[TBL] [Abstract][Full Text] [Related]
31. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG
Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963
[TBL] [Abstract][Full Text] [Related]
32. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.
Zinzani PL; Stefoni V; Tani M; Fanti S; Musuraca G; Castellucci P; Marchi E; Fina M; Ambrosini V; Pellegrini C; Alinari L; Derenzini E; Montini G; Broccoli A; Bacci F; Pileri S; Baccarani M
J Clin Oncol; 2009 Apr; 27(11):1781-7. PubMed ID: 19273712
[TBL] [Abstract][Full Text] [Related]
33. FDG PET scan strategies and long-term outcomes after first-line therapy in Hodgkin's disease.
Poulou LS; Karianakis G; Ziakas PD
Eur J Radiol; 2009 Jun; 70(3):499-506. PubMed ID: 18342471
[TBL] [Abstract][Full Text] [Related]
34. Positron emission tomography scanning in the assessment of patients with lymphoma.
Foo SS; Mitchell PL; Berlangieri SU; Smith CL; Scott AM
Intern Med J; 2004 Jul; 34(7):388-97. PubMed ID: 15271172
[TBL] [Abstract][Full Text] [Related]
35. [Predictive value of positron emission tomography with 18F-FDG in the diagnosis and staging of patients with Hodgkin's lymphoma].
Khodzhibekova MM
Vopr Onkol; 2013; 59(4):470-4. PubMed ID: 24032221
[TBL] [Abstract][Full Text] [Related]
36. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
[TBL] [Abstract][Full Text] [Related]
37. [18FDG-PET/CT cost-effectiveness compared to CT at the end of treatment in pediatric Hodgkin's lymphoma patients].
García-Molina M; Chicaíza-Becerra L; Moreno-Calderon A; Prieto-Martínez V; Sarmiento-Urbina I; Linares-Ballesteros A
Rev Salud Publica (Bogota); 2014; 16(2):260-9. PubMed ID: 25383499
[TBL] [Abstract][Full Text] [Related]
38. Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?
Brepoels L; Stroobants S
Hematol Oncol Clin North Am; 2007 Oct; 21(5):855-69. PubMed ID: 17908624
[TBL] [Abstract][Full Text] [Related]
39. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma.
Rodriguez M
Acta Radiol Suppl; 1998; 417():1-36. PubMed ID: 9645167
[TBL] [Abstract][Full Text] [Related]
40. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
